Marksans Pharma Ltd shared the transcript of their Q1 FY 2026 earnings call held on August 13, 2025, discussing financial performance and strategy updates. Key points included onetime expenses including an INR 10.48 crore ECL provision and INR 6.2 crore mark-to-market provision.